340B Advocacy Alliance Bulletin
Deceptively branded as an effort to save the 340B program, a legislative campaign by the Pharmaceutical Research and Manufacturers of America, National Association of Community Health Centers and other groups to remove many hospitals, eligible drugs and patients from the 340B program “would only…
AHA slams group’s proposal that would hurt 340B Program
The AHA today responded to a new group that includes the Pharmaceutical Research and Manufacturers of America, National Association of Community Health Centers and other organizations calling for legislative changes that would hurt the 340B…
Following the recent district court decision to remand to the Department of Health and Human Services the question of how to repay 340B hospitals for funds unlawfully withheld for five years,
Drugmakers that participate in the 340B drug pricing program do not have to provide discounted 340B drugs to an unlimited number of contract pharmacies, the U.S. Court of Appeals for the 3rd Circuit ruled today in Sanofi-Aventis U.S. v. HHS et al. Cases raising similar legal questions are pending…
AHA 340B Hospital Members Urged to Submit Comments on HRSA’s Proposed Rule on the 340B Administrative Dispute Resolution Process, Model Comment Letter Available
The U.S. District Court for the District of Columbia today decided to allow the Department of Health and Human Services to propose an appropriate remedy for its past underpayments to hospitals participating in the 340B Drug Pricing Program.
Article in WSJ spotlights 340B; resources to assist.
Digital ad campaign from AHA, others spotlights the importance and value of the 340B program The AHA, along with six other national hospital groups, is running a new digital ad campaign promoting to policymakers and influencers the benefits of the 340B program to patients and communities
The AHA today released a new report showing how the unlawful actions of drug companies to limit 340B pricing with community and specialty pharmacies are having an adverse impact on access to care for patients and communities across the country.
The AHA has issued a Special Bulletin with details on provisions of the Centers for Medicare & Medicaid Services’ outpatient prospective payment system final rule for calendar year 2023, which includes updates to policies for the 340B Drug Pricing Program.